Nantkwest, inc. (NK)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15
Operating activities:
Net loss

-66,287

-65,789

-67,488

-75,542

-86,592

-96,226

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-

-

-

-

-

-

-

-

-

-

0

0

-114,647

-

-123,393

-137,808

-234,704

-236,876

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

8,834

9,012

9,590

10,164

10,327

9,555

8,337

7,022

6,027

5,566

5,836

5,145

4,284

3,607

2,259

1,484

1,931

1,472

0

0

0

Non-cash lease expense related to operating lease right-of-use assets

2,654

2,604

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Stock-based compensation expense

1,721

2,627

3,557

7,248

15,660

23,382

30,859

35,605

36,052

36,997

39,379

49,334

63,308

73,852

83,992

104,302

207,260

211,221

0

0

0

Amortization of operating lease right-of-use assets

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of net premiums and discounts on marketable debt securities

-4

0

-70

-121

-303

-463

-681

-1,000

-1,226

-1,597

-1,913

-2,179

-2,328

-2,182

0

0

0

-

-

-

-

Non-cash interest items, net

-358

-246

-141

-263

-47

-291

-395

-341

-616

-720

-348

-413

25

573

0

0

0

-

-

-

-

Loss on disposal of assets

-

-

-

-

-

-

-

-

-100

-64

-64

0

-3

-18

0

0

0

-

-

-

-

Deferred income tax benefit

-

-

-

-

-

-498

-558

-528

-528

-497

-467

-419

-523

-575

0

0

0

-

-

-

-

Loss on sales of marketable debt securities

0

-

-

-

0

-

-

-

-

-

-

-

-

137

0

0

0

-

-

-

-

Change in value of warrant liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,366

0

0

0

Loss incurred by Inex Bio

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-56

0

0

0

Gain on settlement of note payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

133

0

0

0

Accounts receivable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Prepaid expenses and other current assets

-9,440

-9,276

-10,066

-1,571

8,891

9,818

12,937

-930

678

-156

0

0

0

-

-

-

3,462

3,231

0

0

0

Operating lease right-of-use assets, net

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other assets

0

-

-

-

0

-

-

-

-

-458

-542

-767

-616

-153

-74

-2,236

1,444

1,194

0

0

0

Operating lease right-of-use assets

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Accounts payable

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accounts payable

-

-

-

-

-

-

-

0

-458

-

2,060

-263

2,350

888

-2,867

-1,337

-209

627

0

0

0

Accrued expenses and other liabilities

0

-

-

-

0

-

-

-

1,145

-299

-773

-615

1,325

2,127

3,461

1,317

3,230

1,991

0

0

0

Due to related parties

-631

-1,093

-1,342

-859

-867

-685

621

-375

268

1,562

636

1,432

1,370

378

0

0

0

-

-

-

-

Operating lease liabilities

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Operating lease liability, less current portion

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Deferred rent and revenue

-

-

-

-

-

-508

-491

-465

1,123

1,201

1,441

2,159

1,219

1,754

2,478

1,859

1,296

737

0

0

0

Net cash used in operating activities

-60,880

-61,362

-60,510

-61,509

-60,948

-63,381

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Investing activities:
Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-39,794

-

-38,784

-32,300

-26,789

-25,305

0

0

0

Purchases of property, plant and equipment

2,224

4,182

5,547

8,797

10,304

13,102

22,490

29,544

35,208

34,815

24,740

17,102

10,002

6,560

6,157

4,212

3,270

2,241

0

0

0

Purchase of Viracta common stock

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

Purchase of Viracta common stock

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

0

-

-

-

-

Purchases of marketable debt securities, available-for-sale

46,645

86,618

89,344

108,056

113,005

94,770

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Purchases of marketable debt securities

-

-

-

-

-

-

-

-

-

-

-

-

186,809

-

0

0

0

-

-

-

-

Sales/maturities of marketable debt securities

103,950

112,259

119,709

141,513

158,342

165,284

202,611

199,253

239,828

254,222

244,817

250,530

209,589

165,887

0

0

0

-

-

-

-

Net cash provided by (used in) investing activities

55,078

21,456

25,207

24,707

34,722

57,101

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Financing activities:
Purchase of Inex Bio Inc., net of cash acquired

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,818

0

0

0

Net cash provided by investing activities

-

-

-

-

-

-

-

-

-

-

-

-

4,278

-

-277,328

-284,834

-275,280

-175,224

0

0

0

Principal payments of financing/capital lease obligations

-

-

-

-

-

-

-

-

-

19,932

19,890

4,952

54

32

0

0

0

-

-

-

-

Principal payments of financing lease obligations

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from exercises of stock options and warrants

0

39,221

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Repurchases of common stock with commissions

-

-

-

-

-

-

-

-

-

15,227

16,405

18,979

14,347

15,847

0

0

0

-

-

-

-

Proceeds from exercise of stock options and warrants

-

-

-

-

-

-

-

-

84

-

1,573

1,757

1,919

1,425

0

0

0

-

-

-

0

Net share settlement for restricted stock unit vesting and option exercises

224

127

66

26

106

123

453

453

532

1,039

1,223

1,815

1,656

1,106

0

0

0

-

-

-

-

Net cash (used in) provided by financing activities

-725

38,593

38,284

38,209

38,509

-771

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Repayments of notes payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

132

0

0

0

Net cash used in financing activities

-

-

-

-

-

-

-

-

-

-

-

-

-14,138

-

-11,150

234,920

315,465

317,333

0

0

0

Net increase in cash, cash equivalents, and restricted cash

-6,527

-1,313

2,981

1,407

12,283

-7,051

-5,610

-22,917

-2,400

15,789

0

0

0

-

-

-

-

-

-

-

-

Reconciliation of cash, cash equivalents, and restricted cash at end of period:
Net increase (decrease) in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-327,212

-82,214

13,396

116,804

0

0

0

Supplemental disclosure of cash flow information:
Interest

23

19

266

299

444

475

253

609

665

668

669

304

103

66

0

0

0

-

-

-

-

Income taxes

3

3

3

3

4

4

4

4

3

3

4

4

1

2

-4

1

1

1

0

0

0

Supplemental disclosure of non-cash investing and financing activities:
Property and equipment purchases included in accounts payable, accrued expenses, and other liabilities

-1,775

74

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Conversion of Viracta convertible notes and accrued interest into investment in equity securities of Viracta (Note 4)

0

751

751

751

751

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Unrealized (losses) gains on marketable debt securities

117

258

361

430

415

123

-172

-238

-341

-97

-500

-990

-828

-102

0

0

0

-

-

-

-

Property and equipment purchases included in accounts payable, accrued expenses, and other liabilities

-

-

-

-

-

-

-

-

12,938

-

19,222

14,096

4,171

2,753

0

0

0

-

-

-

-

Cashless exercise of stock options

0

29

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cashless exercise of stock options

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-